BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in
the United States in 2010. We describe invasive pneumococcal disease (IPD) in children at …

Background: The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced for
routine administration to infants and children in 2010 in the United States. We have …

Background: In 2000, a 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for
use among US children. Many sites have since reported changes in invasive pneumococcal …

OBJECTIVES We sought to describe the evolving epidemiology of invasive pneumococcal
disease (IPD) among children in Massachusetts, United States, over the last 2 decades …

Importance Invasive pneumococcal disease (IPD) is a leading cause of pneumonia,
meningitis, and bacteremia in children. In March 2010, a 13-valent pneumococcal conjugate …

Abstract Background In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13)
replaced 7-valent PCV (PCV7) for protection against invasive pneumococcal disease (IPD) …

OBJECTIVE: To examine whether there is a different clinical profile and severity of invasive
pneumococcal disease (IPD) in children caused by nonvaccine types in the era of 13-valent …

Background: The seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in
Canada in 2001. Routine infant vaccination programs in Alberta began in 2002. Several …

Background. The impact of PCV13 on a number of clinical aspects of pneumococcal
pneumonia (PP) in children has not been reported. We compared the serotype distribution …

Invasive pneumococcal disease (IPD), caused by Streptococcus pneumoniae
(pneumococcus), remains a leading cause of serious illness in children and adults …